Kansas City, KS3 Active Studies

Myasthenia Gravis Clinical Trials in Kansas City, KS

Find 3 actively recruiting myasthenia gravis clinical trials in Kansas City, KS. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
246
Enrolling

Recruiting Myasthenia Gravis Studies in Kansas City

About Myasthenia Gravis Clinical Trials in Kansas City

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.

There are currently 3 myasthenia gravis clinical trials recruiting participants in Kansas City, KS. These studies are seeking a combined 246 participants. Research is being sponsored by RemeGen Co., Ltd., COUR Pharmaceutical Development Company, Inc., Cabaletta Bio. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myasthenia Gravis Clinical Trials in Kansas City — FAQ

Are there myasthenia gravis clinical trials in Kansas City?

Yes, there are 3 myasthenia gravis clinical trials currently recruiting in Kansas City, KS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Kansas City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.

Are clinical trials in Kansas City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.

What myasthenia gravis treatments are being tested?

The 3 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.

Data updated March 2, 2026 from ClinicalTrials.gov